Fig 1. Anti-leukemic effect of ribavirin alone or combined with imatinib in Ph+ leukemia cell lines.

A. SUP-B15 cells were treated with 30, 60, 90, and 120μM ribavirin for 24, 48, 72, and 96h. Cell proliferation was assessed by the MTT assay and cell survival rates were presented. B. SUP-B15 cells were treated with a series of concentrations of imatinib (0.001–20μM) alone or combined with 10μM or 20μM ribavirin for 72h, the IC₅₀ values of imatinib were shown. C. K562 cells were treated with 1μM imatinib or combined with 10μM ribavirin for 72h, the IC₅₀ values of imatinib were shown. The data represent means±SD of three experiments. * represents p<0.05, ** represents p<0.01.